

**TDMS No.** 99017 - 06

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Diethylamine

**CAS Number:** 109-89-7

F1\_M3

**Date Report Requested:** 10/23/2008

**Time Report Requested:** 13:20:12

**First Dose M/F:** 08/18/03 / 08/18/03

**Lab:** BNW

**C Number:** C99017  
**Lock Date:** 08/01/2006  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.0.0

TDMS No. 99017 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Diethylamine

CAS Number: 109-89-7

Date Report Requested: 10/23/2008

Time Report Requested: 13:20:12

First Dose M/F: 08/18/03 / 08/18/03

Lab: BNW

**SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Diethylamine**

**MALE MICE**

**Organ**

Adrenal Cortex

Heart

Heart: Artery

Liver

Lung

Nose

Nose: Glands, Respiratory Epithelium

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Nose: Turbinate

Pituitary Gland: Pars Distalis

Preputial Gland

Skin

Spleen

Stomach, Glandular

**Morphology**

Accessory Adrenal Cortical Nodule

Hyperplasia

Hypertrophy

Cardiomyopathy

Inflammation

Basophilic Focus

Congestion

Degeneration Fatty

Eosinophilic Focus

Mixed Cell Focus

Tension Lipidosis

Hemorrhage

Infiltration Cellular Histiocyte

Inflammation

Accumulation, Hyaline Droplet

Hyperplasia

Accumulation, Hyaline Droplet

Atrophy

Respiratory Metaplasia

Vacuolization Cytoplasmic

Accumulation, Hyaline Droplet

Metaplasia

Necrosis

Vacuolization Cytoplasmic

Hyperostosis

Hyperplasia

Ectasia

Inflammation

Ulcer

Hematopoietic Cell Proliferation

Hyperplasia

TDMS No. 99017 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Diethylamine

CAS Number: 109-89-7

Date Report Requested: 10/23/2008

Time Report Requested: 13:20:12

First Dose M/F: 08/18/03 / 08/18/03

Lab: BNW

**SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Diethylamine**

**FEMALE MICE**

**Organ**

Adrenal Medulla

Heart

Heart: Capillary

Kidney

Liver

Lymph Node, Mandibular

Nose

Nose: Glands, Respiratory Epithelium

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Nose: Turbinate

Pituitary Gland: Pars Distalis

Stomach, Forestomach

Thyroid Gland

Uterus: Endometrium

**Morphology**

Hyperplasia

Cardiomyopathy

Hyperplasia

Metaplasia Osseous

Nephropathy

Basophilic Focus

Hyperplasia Lymphoid

Inflammation

Accumulation, Hyaline Droplet

Hyperplasia

Inflammation Chronic

Accumulation, Hyaline Droplet

Atrophy

Respiratory Metaplasia

Vacuolization Cytoplasmic

Accumulation, Hyaline Droplet

Metaplasia

Necrosis

Ulcer

Hyperostosis

Hyperplasia

Hyperplasia

Inflammation

Cyst

Hyperplasia Cystic

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Cortex  
Accessory Adrenal Cortical Nodule**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	3/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	7%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	3/32 (9%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.575	(e)	P=0.120	(e)
POLY 1.5	P=0.564	(e)	P=0.119	(e)
POLY 6	P=0.590	(e)	P=0.121	(e)
COCH-ARM / FISHERS	P=0.549	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.178	(e)	P=0.039*	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Cortex  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Cortex  
Hyperplasia**

**LESION RATES**

OVERALL (a)	10/50 (20%)	12/50 (24%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	10/43.61	12/45.99	4/43.93	5/45.58
POLY-3 PERCENT (g)	22.9%	26.1%	9.1%	11%
TERMINAL (d)	7/31 (23%)	11/38 (29%)	2/32 (6%)	4/37 (11%)
FIRST INCIDENCE	606	666	484	662

**STATISTICAL TESTS**

POLY 3	P=0.033N*	P=0.459	P=0.068N	P=0.108N
POLY 1.5	P=0.036N*	P=0.435	P=0.070N	P=0.118N
POLY 6	P=0.029N*	P=0.494	P=0.065N	P=0.096N
COCH-ARM / FISHERS	P=0.042N*	P=0.405	P=0.074N	P=0.131N
MAX-ISO-POLY-3	P=0.050N*	P=0.366	P=0.037N*	P=0.068N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Cortex  
Hypertrophy**

**LESION RATES**

OVERALL (a)	37/50 (74%)	31/50 (62%)	26/50 (52%)	26/50 (52%)
POLY-3 RATE (b)	37/45.60	31/46.69	26/43.64	26/45.37
POLY-3 PERCENT (g)	81.1%	66.4%	59.6%	57.3%
TERMINAL (d)	28/31 (90%)	28/38 (74%)	24/32 (75%)	25/37 (68%)
FIRST INCIDENCE	583	541	609	717

**STATISTICAL TESTS**

POLY 3	P=0.010N**	P=0.072N	P=0.014N*	P=0.008N**
POLY 1.5	P=0.011N*	P=0.097N	P=0.015N*	P=0.011N*
POLY 6	P=0.008N**	P=0.049N*	P=0.015N*	P=0.005N**
COCH-ARM / FISHERS	P=0.016N*	P=0.142N	P=0.019N*	P=0.019N*
MAX-ISO-POLY-3	P=0.008N**	P=0.045N*	P=0.008N**	P=0.004N**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Cortex  
Vacuolization Cytoplasmic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.80	1/43.20	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	2.3%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	---	718	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.582N	P=0.513	P=0.502	(e)
POLY 1.5	P=0.589N	P=0.507	P=0.500	(e)
POLY 6	P=0.572N	P=0.522	P=0.504	(e)
COCH-ARM / FISHERS	P=0.597N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.415N	P=0.175	P=0.160	(e)

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Medulla  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	0%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	---	---

**STATISTICAL TESTS**

POLY 3	P=0.565N	P=0.513	(e)	(e)
POLY 1.5	P=0.570N	P=0.507	(e)	(e)
POLY 6	P=0.558N	P=0.521	(e)	(e)
COCH-ARM / FISHERS	P=0.575N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.399N	P=0.174	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Brain  
Atrophy**

**LESION RATES**

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.14	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	656	---	---	---

**STATISTICAL TESTS**

POLY 3	P=0.318N	P=0.488N	P=0.500N	P=0.490N
POLY 1.5	P=0.313N	P=0.493N	P=0.500N	P=0.495N
POLY 6	P=0.324N	P=0.481N	P=0.499N	P=0.484N
COCH-ARM / FISHERS	P=0.307N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.123N	P=0.158N	P=0.158N	P=0.158N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Epididymis  
Granuloma Sperm**

**LESION RATES**

OVERALL (a)	0/49 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.09	1/45.75	0/43.20	2/45.89
POLY-3 PERCENT (g)	0%	2.2%	0%	4.4%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	1/37 (3%)
FIRST INCIDENCE	---	729 (T)	---	554

**STATISTICAL TESTS**

POLY 3	P=0.149	P=0.517	(e)	P=0.257
POLY 1.5	P=0.145	P=0.511	(e)	P=0.250
POLY 6	P=0.154	P=0.524	(e)	P=0.266
COCH-ARM / FISHERS	P=0.140	P=0.505	(e)	P=0.253
MAX-ISO-POLY-3	P=0.100	P=0.178	(e)	P=0.094

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Eye  
Cataract**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	2/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	2/32 (6%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.625	(e)	P=0.239	(e)
POLY 1.5	P=0.616	(e)	P=0.238	(e)
POLY 6	P=0.638	(e)	P=0.241	(e)
COCH-ARM / FISHERS	P=0.603	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.263	(e)	P=0.077	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

Eye: Cornea  
Inflammation Chronic

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.87	2/45.75	0/43.20	2/45.33
POLY-3 PERCENT (g)	0%	4.4%	0%	4.4%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	0/32 (0%)	2/37 (5%)
FIRST INCIDENCE	---	729 (T)	---	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.258	P=0.252	(e)	P=0.250
POLY 1.5	P=0.251	P=0.245	(e)	P=0.244
POLY 6	P=0.269	P=0.262	(e)	P=0.258
COCH-ARM / FISHERS	P=0.243	P=0.247	(e)	P=0.247
MAX-ISO-POLY-3	P=0.139	P=0.090	(e)	P=0.088

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Harderian Gland  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.75	1/43.20	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	2.3%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.582N	P=0.513	P=0.502	(e)
POLY 1.5	P=0.589N	P=0.507	P=0.500	(e)
POLY 6	P=0.572N	P=0.521	P=0.504	(e)
COCH-ARM / FISHERS	P=0.597N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.415N	P=0.174	P=0.160	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Heart  
Cardiomyopathy**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	8/50 (16%)	1/50 (2%)
POLY-3 RATE (b)	0/42.87	1/45.75	8/43.22	1/45.33
POLY-3 PERCENT (g)	0%	2.2%	18.5%	2.2%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	7/32 (22%)	1/37 (3%)
FIRST INCIDENCE	---	729 (T)	723	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.329	P=0.513	P=0.004**	P=0.511
POLY 1.5	P=0.313	P=0.507	P=0.004**	P=0.506
POLY 6	P=0.352	P=0.521	P=0.004**	P=0.518
COCH-ARM / FISHERS	P=0.301	P=0.500	P=0.003**	P=0.500
MAX-ISO-POLY-3	P=0.028*	P=0.174	P<0.001**	P=0.172

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Heart: Artery  
Inflammation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	4/46.66
POLY-3 PERCENT (g)	0%	0%	0%	8.6%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	2/37 (5%)
FIRST INCIDENCE	---	---	---	442

**STATISTICAL TESTS**

POLY 3	P=0.003**	(e)	(e)	P=0.072
POLY 1.5	P=0.003**	(e)	(e)	P=0.067
POLY 6	P=0.003**	(e)	(e)	P=0.079
COCH-ARM / FISHERS	P=0.003**	(e)	(e)	P=0.059
MAX-ISO-POLY-3	P=0.004**	(e)	(e)	P=0.028*

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

Heart: Atrium  
Thrombosis

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	2/46.35	1/43.22	0/45.33
POLY-3 PERCENT (g)	0%	4.3%	2.3%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	536	723	---

**STATISTICAL TESTS**

POLY 3	P=0.443N	P=0.255	P=0.502	(e)
POLY 1.5	P=0.454N	P=0.247	P=0.501	(e)
POLY 6	P=0.428N	P=0.266	P=0.504	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.343N	P=0.093	P=0.161	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Heart: Capillary  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Intestine Small, Ileum  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/42.87	2/45.75	1/43.20	0/45.33
POLY-3 PERCENT (g)	2.3%	4.4%	2.3%	0%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.238N	P=0.523	P=0.759N	P=0.489N
POLY 1.5	P=0.244N	P=0.513	P=0.760N	P=0.494N
POLY 6	P=0.230N	P=0.537	P=0.757N	P=0.482N
COCH-ARM / FISHERS	P=0.250N	P=0.500	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.242N	P=0.305	P=0.497N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Islets, Pancreatic  
Hyperplasia**

**LESION RATES**

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/43.26	1/45.75	1/42.77	0/45.33
POLY-3 PERCENT (g)	4.6%	2.2%	2.3%	0%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	620	729 (T)	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.152N	P=0.480N	P=0.504N	P=0.227N
POLY 1.5	P=0.154N	P=0.489N	P=0.506N	P=0.232N
POLY 6	P=0.151N	P=0.468N	P=0.501N	P=0.220N
COCH-ARM / FISHERS	P=0.154N	P=0.500N	P=0.508N	P=0.247N
MAX-ISO-POLY-3	P=0.122N	P=0.270N	P=0.284N	P=0.076N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney  
Cyst**

**LESION RATES**

OVERALL (a)	4/50 (8%)	6/50 (12%)	6/49 (12%)	5/50 (10%)
POLY-3 RATE (b)	4/43.26	6/45.75	6/42.67	5/45.33
POLY-3 PERCENT (g)	9.3%	13.1%	14.1%	11%
TERMINAL (d)	3/31 (10%)	6/38 (16%)	6/32 (19%)	5/37 (14%)
FIRST INCIDENCE	620	729 (T)	729 (T)	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.511	P=0.405	P=0.360	P=0.529
POLY 1.5	P=0.499	P=0.389	P=0.358	P=0.516
POLY 6	P=0.530	P=0.427	P=0.365	P=0.548
COCH-ARM / FISHERS	P=0.483	P=0.370	P=0.357	P=0.500
MAX-ISO-POLY-3	P=0.498	P=0.289	P=0.245	P=0.392

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Kidney  
Infarct**

**LESION RATES**

OVERALL (a)	1/50 (2%)	4/50 (8%)	4/49 (8%)	2/50 (4%)
POLY-3 RATE (b)	1/43.54	4/45.80	4/42.67	2/45.33
POLY-3 PERCENT (g)	2.3%	8.7%	9.4%	4.4%
TERMINAL (d)	0/31 (0%)	3/38 (8%)	4/32 (13%)	2/37 (5%)
FIRST INCIDENCE	503	718	729 (T)	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.545	P=0.194	P=0.172	P=0.514
POLY 1.5	P=0.533	P=0.187	P=0.172	P=0.507
POLY 6	P=0.563	P=0.205	P=0.174	P=0.524
COCH-ARM / FISHERS	P=0.520	P=0.181	P=0.175	P=0.500
MAX-ISO-POLY-3	P=0.260	P=0.098	P=0.080	P=0.296

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Kidney  
Metaplasia Osseous**

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/49 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.87	2/45.75	1/42.67	2/45.58
POLY-3 PERCENT (g)	2.3%	4.4%	2.3%	4.4%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	1/32 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	662

**STATISTICAL TESTS**

POLY 3	P=0.463	P=0.523	P=0.760	P=0.521
POLY 1.5	P=0.453	P=0.513	P=0.758	P=0.512
POLY 6	P=0.477	P=0.537	P=0.759N	P=0.536
COCH-ARM / FISHERS	P=0.442	P=0.500	P=0.747	P=0.500
MAX-ISO-POLY-3	P=0.486	P=0.305	P=0.498	P=0.303

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Kidney  
Nephropathy**

**LESION RATES**

OVERALL (a)	44/50 (88%)	47/50 (94%)	44/49 (90%)	45/50 (90%)
POLY-3 RATE (b)	44/47.14	47/48.58	44/46.49	45/47.62
POLY-3 PERCENT (g)	93.3%	96.8%	94.6%	94.5%
TERMINAL (d)	31/31 (100%)	38/38 (100%)	32/32 (100%)	36/37 (97%)
FIRST INCIDENCE	491	536	442	563

**STATISTICAL TESTS**

POLY 3	P=0.595	P=0.350	P=0.588	P=0.596
POLY 1.5	P=0.556	P=0.284	P=0.540	P=0.532
POLY 6	P=0.591N	P=0.552	P=0.730	P=0.758
COCH-ARM / FISHERS	P=0.548	P=0.243	P=0.514	P=0.500
MAX-ISO-POLY-3	P=0.469	P=0.162	P=0.365	P=0.382

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Larynx  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Basophilic Focus**

**LESION RATES**

OVERALL (a)	5/50 (10%)	13/50 (26%)	10/50 (20%)	8/50 (16%)
POLY-3 RATE (b)	5/43.53	13/47.05	10/43.39	8/45.88
POLY-3 PERCENT (g)	11.5%	27.6%	23.1%	17.4%
TERMINAL (d)	3/31 (10%)	10/38 (26%)	9/32 (28%)	7/37 (19%)
FIRST INCIDENCE	620	484	678	555

**STATISTICAL TESTS**

POLY 3	P=0.495	P=0.046*	P=0.125	P=0.310
POLY 1.5	P=0.473	P=0.040*	P=0.127	P=0.295
POLY 6	P=0.524	P=0.056	P=0.124	P=0.331
COCH-ARM / FISHERS	P=0.447	P=0.033*	P=0.131	P=0.277
MAX-ISO-POLY-3	P=0.153	P=0.030*	P=0.075	P=0.219

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

Liver  
Clear Cell Focus

**LESION RATES**

OVERALL (a)	5/50 (10%)	5/50 (10%)	7/50 (14%)	2/50 (4%)
POLY-3 RATE (b)	5/42.87	5/45.75	7/43.20	2/45.33
POLY-3 PERCENT (g)	11.7%	10.9%	16.2%	4.4%
TERMINAL (d)	5/31 (16%)	5/38 (13%)	7/32 (22%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.172N	P=0.589N	P=0.383	P=0.194N
POLY 1.5	P=0.182N	P=0.607N	P=0.380	P=0.204N
POLY 6	P=0.159N	P=0.562N	P=0.390	P=0.179N
COCH-ARM / FISHERS	P=0.194N	P=0.630N	P=0.380	P=0.218N
MAX-ISO-POLY-3	P=0.167N	P=0.457N	P=0.273	P=0.110N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Congestion**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.08	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	676	---	---	---

**STATISTICAL TESTS**

POLY 3	P=0.120N	P=0.224N	P=0.236N	P=0.226N
POLY 1.5	P=0.117N	P=0.230N	P=0.237N	P=0.231N
POLY 6	P=0.124N	P=0.216N	P=0.235N	P=0.219N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.076N	P=0.076N	P=0.076N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

Liver  
Cyst

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Degeneration Fatty**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.14	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	656	---	---	---

**STATISTICAL TESTS**

POLY 3	P=0.120N	P=0.224N	P=0.237N	P=0.226N
POLY 1.5	P=0.117N	P=0.230N	P=0.237N	P=0.231N
POLY 6	P=0.124N	P=0.216N	P=0.235N	P=0.219N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.076N	P=0.076N	P=0.076N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Eosinophilic Focus**

**LESION RATES**

OVERALL (a)	2/50 (4%)	8/50 (16%)	6/50 (12%)	7/50 (14%)
POLY-3 RATE (b)	2/43.26	8/45.75	6/43.89	7/45.37
POLY-3 PERCENT (g)	4.6%	17.5%	13.7%	15.4%
TERMINAL (d)	1/31 (3%)	8/38 (21%)	4/32 (13%)	6/37 (16%)
FIRST INCIDENCE	620	729 (T)	506	717

**STATISTICAL TESTS**

POLY 3	P=0.174	P=0.054	P=0.136	P=0.090
POLY 1.5	P=0.164	P=0.050*	P=0.135	P=0.085
POLY 6	P=0.189	P=0.061	P=0.139	P=0.098
COCH-ARM / FISHERS	P=0.154	P=0.046*	P=0.134	P=0.080
MAX-ISO-POLY-3	P=0.104	P=0.029*	P=0.072	P=0.048*

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Mixed Cell Focus**

**LESION RATES**

OVERALL (a)	0/50 (0%)	4/50 (8%)	1/50 (2%)	5/50 (10%)
POLY-3 RATE (b)	0/42.87	4/45.75	1/43.22	5/45.37
POLY-3 PERCENT (g)	0%	8.7%	2.3%	11%
TERMINAL (d)	0/31 (0%)	4/38 (11%)	0/32 (0%)	4/37 (11%)
FIRST INCIDENCE	---	729 (T)	723	717

**STATISTICAL TESTS**

POLY 3	P=0.053	P=0.069	P=0.502	P=0.035*
POLY 1.5	P=0.050*	P=0.065	P=0.501	P=0.033*
POLY 6	P=0.058	P=0.075	P=0.504	P=0.039*
COCH-ARM / FISHERS	P=0.048*	P=0.059	P=0.500	P=0.028*
MAX-ISO-POLY-3	P=0.021*	P=0.026*	P=0.161	P=0.013*

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Necrosis**

**LESION RATES**

OVERALL (a)	4/50 (8%)	1/50 (2%)	4/50 (8%)	3/50 (6%)
POLY-3 RATE (b)	4/43.77	1/45.75	4/43.92	3/45.37
POLY-3 PERCENT (g)	9.1%	2.2%	9.1%	6.6%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	2/32 (6%)	2/37 (5%)
FIRST INCIDENCE	583	729 (T)	618	717

**STATISTICAL TESTS**

POLY 3	P=0.571N	P=0.165N	P=0.642N	P=0.480N
POLY 1.5	P=0.573N	P=0.171N	P=0.643N	P=0.489N
POLY 6	P=0.568N	P=0.157N	P=0.638N	P=0.468N
COCH-ARM / FISHERS	P=0.576N	P=0.181N	P=0.643N	P=0.500N
MAX-ISO-POLY-3	P=0.444N	P=0.080N	P=0.497N	P=0.332N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Tension Lipidosis**

**LESION RATES**

OVERALL (a)	1/50 (2%)	6/50 (12%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	1/43.26	6/45.75	2/43.61	3/45.33
POLY-3 PERCENT (g)	2.3%	13.1%	4.6%	6.6%
TERMINAL (d)	0/31 (0%)	6/38 (16%)	1/32 (3%)	3/37 (8%)
FIRST INCIDENCE	620	729 (T)	610	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.524	P=0.065	P=0.503	P=0.322
POLY 1.5	P=0.510	P=0.061	P=0.501	P=0.315
POLY 6	P=0.544	P=0.071	P=0.507	P=0.333
COCH-ARM / FISHERS	P=0.494	P=0.056	P=0.500	P=0.309
MAX-ISO-POLY-3	P=0.227	P=0.031*	P=0.283	P=0.172

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung  
Hemorrhage**

**LESION RATES**

OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/43.30	0/45.75	2/43.22	1/45.33
POLY-3 PERCENT (g)	6.9%	0%	4.6%	2.2%
TERMINAL (d)	2/31 (7%)	0/38 (0%)	1/32 (3%)	1/37 (3%)
FIRST INCIDENCE	606	---	723	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.334N	P=0.109N	P=0.501N	P=0.289N
POLY 1.5	P=0.334N	P=0.113N	P=0.501N	P=0.296N
POLY 6	P=0.335N	P=0.103N	P=0.499N	P=0.278N
COCH-ARM / FISHERS	P=0.333N	P=0.121N	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.182N	P=0.038N*	P=0.324N	P=0.148N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung  
Infiltration Cellular Histiocyte**

**LESION RATES**

OVERALL (a)	12/50 (24%)	1/50 (2%)	7/50 (14%)	3/50 (6%)
POLY-3 RATE (b)	12/43.99	1/45.99	7/44.20	3/45.82
POLY-3 PERCENT (g)	27.3%	2.2%	15.8%	6.6%
TERMINAL (d)	7/31 (23%)	0/38 (0%)	3/32 (9%)	2/37 (5%)
FIRST INCIDENCE	609	666	506	581

**STATISTICAL TESTS**

POLY 3	P=0.026N*	P<0.001N**	P=0.146N	P=0.008N**
POLY 1.5	P=0.027N*	P<0.001N**	P=0.149N	P=0.009N**
POLY 6	P=0.025N*	P<0.001N**	P=0.141N	P=0.006N**
COCH-ARM / FISHERS	P=0.031N*	P<0.001N**	P=0.154N	P=0.011N*
MAX-ISO-POLY-3	P=0.002N**	P<0.001N**	P=0.095N	P=0.004N**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung: Alveolar Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	3/50 (6%)	2/50 (4%)	5/50 (10%)	2/50 (4%)
POLY-3 RATE (b)	3/43.56	2/46.34	5/43.20	2/45.33
POLY-3 PERCENT (g)	6.9%	4.3%	11.6%	4.4%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	5/32 (16%)	2/37 (5%)
FIRST INCIDENCE	609	541	729 (T)	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.487N	P=0.472N	P=0.351	P=0.482N
POLY 1.5	P=0.491N	P=0.484N	P=0.353	P=0.490N
POLY 6	P=0.480N	P=0.456N	P=0.350	P=0.471N
COCH-ARM / FISHERS	P=0.496N	P=0.500N	P=0.357	P=0.500N
MAX-ISO-POLY-3	P=0.456N	P=0.304N	P=0.227	P=0.311N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung: Arteriole  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	2/46.35	1/43.22	0/45.33
POLY-3 PERCENT (g)	0%	4.3%	2.3%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	536	723	---

**STATISTICAL TESTS**

POLY 3	P=0.443N	P=0.255	P=0.502	(e)
POLY 1.5	P=0.454N	P=0.247	P=0.501	(e)
POLY 6	P=0.428N	P=0.266	P=0.504	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.343N	P=0.093	P=0.161	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lymph Node, Mandibular  
Hyperplasia Lymphoid**

**LESION RATES**

OVERALL (a)	0/16 (0%)	0/20 (0%)	0/18 (0%)	0/20 (0%)
POLY-3 RATE (b)	0/13.36	0/17.77	0/15.29	0/18.26
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/13 (0%)	0/11 (0%)	0/14 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lymph Node, Mesenteric  
Infiltration Cellular**

**LESION RATES**

OVERALL (a)	2/49 (4%)	3/47 (6%)	1/48 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/42.92	3/43.42	1/41.77	0/45.33
POLY-3 PERCENT (g)	4.7%	6.9%	2.4%	0%
TERMINAL (d)	0/30 (0%)	1/36 (3%)	1/31 (3%)	0/37 (0%)
FIRST INCIDENCE	509	620	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.097N	P=0.505	P=0.510N	P=0.225N
POLY 1.5	P=0.100N	P=0.494	P=0.509N	P=0.229N
POLY 6	P=0.094N	P=0.523	P=0.509N	P=0.219N
COCH-ARM / FISHERS	P=0.102N	P=0.480	P=0.508N	P=0.242N
MAX-ISO-POLY-3	P=0.114N	P=0.331	P=0.290N	P=0.075N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Mesentery  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	2/10 (20%)	1/6 (17%)	1/4 (25%)	1/8 (13%)
POLY-3 RATE (b)	2/9.06	1/5.70	1/2.88	1/7.75
POLY-3 PERCENT (g)	22.1%	17.5%	34.8%	12.9%
TERMINAL (d)	0/4 (0%)	1/5 (20%)	0/1 (0%)	1/7 (14%)
FIRST INCIDENCE	584	729 (T)	723	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.460N	P=0.666N	P=0.621	P=0.557N
POLY 1.5	P=0.468N	P=0.672N	P=0.647	P=0.567N
POLY 6	P=0.448N	P=0.659N	P=0.592	P=0.543N
COCH-ARM / FISHERS	P=0.474N	P=0.696N	P=0.670	P=0.588N
MAX-ISO-POLY-3	P=0.508N	P=0.426N	P=0.379	P=0.323N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Mesentery: Fat  
Necrosis**

**LESION RATES**

OVERALL (a)	5/10 (50%)	4/6 (67%)	1/4 (25%)	4/8 (50%)
POLY-3 RATE (b)	5/9.67	4/5.70	1/2.85	4/8.00
POLY-3 PERCENT (g)	51.7%	70.2%	35.1%	50%
TERMINAL (d)	2/4 (50%)	4/5 (80%)	1/1 (100%)	3/7 (43%)
FIRST INCIDENCE	561	729 (T)	729 (T)	662

**STATISTICAL TESTS**

POLY 3	P=0.498N	P=0.433	P=0.564N	P=0.651N
POLY 1.5	P=0.505N	P=0.441	P=0.497N	P=0.662N
POLY 6	P=0.476N	P=0.423	P=0.638N	P=0.631N
COCH-ARM / FISHERS	P=0.504N	P=0.451	P=0.406N	P=0.681N
MAX-ISO-POLY-3	P=0.494N	P=0.271	P=0.366N	P=0.473N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose  
Inflammation**

**LESION RATES**

OVERALL (a)	6/50 (12%)	5/50 (10%)	6/50 (12%)	14/50 (28%)
POLY-3 RATE (b)	6/44.16	5/46.89	6/44.64	14/46.35
POLY-3 PERCENT (g)	13.6%	10.7%	13.4%	30.2%
TERMINAL (d)	3/31 (10%)	2/38 (5%)	2/32 (6%)	12/37 (32%)
FIRST INCIDENCE	589	484	506	442

**STATISTICAL TESTS**

POLY 3	P=0.009**	P=0.458N	P=0.614N	P=0.047*
POLY 1.5	P=0.009**	P=0.476N	P=0.616N	P=0.043*
POLY 6	P=0.009**	P=0.435N	P=0.610N	P=0.052
COCH-ARM / FISHERS	P=0.010**	P=0.500N	P=0.620N	P=0.039*
MAX-ISO-POLY-3	P=0.014*	P=0.339N	P=0.491N	P=0.029*

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Glands, Respiratory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	5/50 (10%)	5/50 (10%)	16/50 (32%)	33/50 (66%)
POLY-3 RATE (b)	5/43.26	5/46.47	16/44.53	33/48.10
POLY-3 PERCENT (g)	11.6%	10.8%	35.9%	68.6%
TERMINAL (d)	4/31 (13%)	3/38 (8%)	10/32 (31%)	25/37 (68%)
FIRST INCIDENCE	620	561	609	442

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.585N	P=0.006**	P<0.001**
POLY 1.5	P<0.001**	P=0.605N	P=0.006**	P<0.001**
POLY 6	P<0.001**	P=0.556N	P=0.007**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.630N	P=0.006**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.453N	P=0.003**	P<0.001**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Glands, Respiratory Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	42/50 (84%)	41/50 (82%)	44/50 (88%)	50/50 (100%)
POLY-3 RATE (b)	42/48.44	41/49.88	44/48.59	50/50.00
POLY-3 PERCENT (g)	86.7%	82.2%	90.6%	100%
TERMINAL (d)	26/31 (84%)	31/38 (82%)	29/32 (91%)	37/37 (100%)
FIRST INCIDENCE	491	484	484	442

**STATISTICAL TESTS**

POLY 3	P=0.004**	P=0.366N	P=0.386	P=0.007**
POLY 1.5	P=0.003**	P=0.420N	P=0.382	P=0.005**
POLY 6	P=0.005**	P=0.308N	P=0.395	P=0.012*
COCH-ARM / FISHERS	P=0.003**	P=0.500N	P=0.387	P=0.003**
MAX-ISO-POLY-3	P=0.005**	P=0.269N	P=0.266	P=0.002**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Glands, Respiratory Epithelium  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	6/50 (12%)	9/50 (18%)	8/50 (16%)	11/50 (22%)
POLY-3 RATE (b)	6/43.67	9/47.00	8/43.39	11/47.23
POLY-3 PERCENT (g)	13.7%	19.2%	18.4%	23.3%
TERMINAL (d)	3/31 (10%)	7/38 (18%)	6/32 (19%)	6/37 (16%)
FIRST INCIDENCE	606	484	705	442

**STATISTICAL TESTS**

POLY 3	P=0.171	P=0.342	P=0.380	P=0.184
POLY 1.5	P=0.157	P=0.319	P=0.382	P=0.166
POLY 6	P=0.191	P=0.371	P=0.380	P=0.211
COCH-ARM / FISHERS	P=0.139	P=0.288	P=0.387	P=0.143
MAX-ISO-POLY-3	P=0.211	P=0.253	P=0.277	P=0.130

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Olfactory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	7/50 (14%)	2/50 (4%)	4/50 (8%)	6/50 (12%)
POLY-3 RATE (b)	7/43.30	2/46.30	4/44.76	6/45.81
POLY-3 PERCENT (g)	16.2%	4.3%	8.9%	13.1%
TERMINAL (d)	6/31 (19%)	1/38 (3%)	0/32 (0%)	5/37 (14%)
FIRST INCIDENCE	606	561	442	583

**STATISTICAL TESTS**

POLY 3	P=0.530	P=0.063N	P=0.241N	P=0.456N
POLY 1.5	P=0.526	P=0.070N	P=0.250N	P=0.476N
POLY 6	P=0.536	P=0.055N	P=0.228N	P=0.428N
COCH-ARM / FISHERS	P=0.520	P=0.080N	P=0.262N	P=0.500N
MAX-ISO-POLY-3	P=0.217N	P=0.034N*	P=0.156N	P=0.345N

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium  
Atrophy**

**LESION RATES**

OVERALL (a)	9/50 (18%)	19/50 (38%)	50/50 (100%)	50/50 (100%)
POLY-3 RATE (b)	9/44.17	19/46.80	50/50.00	50/50.00
POLY-3 PERCENT (g)	20.4%	40.6%	100%	100%
TERMINAL (d)	6/31 (19%)	15/38 (40%)	32/32 (100%)	37/37 (100%)
FIRST INCIDENCE	584	561	442	442

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.028*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.025*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.035*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.022*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.019*	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Olfactory Epithelium  
Necrosis**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	2/46.84	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	4.3%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	484	---	---

**STATISTICAL TESTS**

POLY 3	P=0.393N	P=0.257	(e)	(e)
POLY 1.5	P=0.402N	P=0.249	(e)	(e)
POLY 6	P=0.379N	P=0.270	(e)	(e)
COCH-ARM / FISHERS	P=0.415N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.269N	P=0.095	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Olfactory Epithelium  
Respiratory Metaplasia**

**LESION RATES**

OVERALL (a)	14/50 (28%)	15/50 (30%)	44/50 (88%)	50/50 (100%)
POLY-3 RATE (b)	14/43.36	15/48.10	44/49.10	50/50.00
POLY-3 PERCENT (g)	32.3%	31.2%	89.6%	100%
TERMINAL (d)	12/31 (39%)	9/38 (24%)	28/32 (88%)	37/37 (100%)
FIRST INCIDENCE	589	484	442	442

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.545N	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.576	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.468N	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.456N	P<0.001**	P<0.001**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Olfactory Epithelium  
Vacuolization Cytoplasmic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	5/50 (10%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	5/46.95	3/44.20	0/45.33
POLY-3 PERCENT (g)	0%	10.7%	6.8%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	536	609	---

**STATISTICAL TESTS**

POLY 3	P=0.278N	P=0.039*	P=0.124	(e)
POLY 1.5	P=0.295N	P=0.035*	P=0.121	(e)
POLY 6	P=0.255N	P=0.045*	P=0.129	(e)
COCH-ARM / FISHERS	P=0.318N	P=0.028*	P=0.121	(e)
MAX-ISO-POLY-3	P=0.146N	P=0.016*	P=0.042*	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Respiratory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	11/50 (22%)	6/50 (12%)	19/50 (38%)	30/50 (60%)
POLY-3 RATE (b)	11/44.57	6/47.00	19/46.01	30/48.50
POLY-3 PERCENT (g)	24.7%	12.8%	41.3%	61.9%
TERMINAL (d)	7/31 (23%)	4/38 (11%)	11/32 (34%)	21/37 (57%)
FIRST INCIDENCE	589	484	442	442

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.114N	P=0.069	P<0.001**
POLY 1.5	P<0.001**	P=0.126N	P=0.065	P<0.001**
POLY 6	P<0.001**	P=0.102N	P=0.076	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.143N	P=0.063	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.075N	P=0.046*	P<0.001**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Respiratory Epithelium  
Metaplasia**

**LESION RATES**

OVERALL (a)	4/50 (8%)	7/50 (14%)	16/50 (32%)	34/50 (68%)
POLY-3 RATE (b)	4/44.16	7/47.12	16/43.74	34/48.18
POLY-3 PERCENT (g)	9.1%	14.9%	36.6%	70.6%
TERMINAL (d)	1/31 (3%)	3/38 (8%)	12/32 (38%)	25/37 (68%)
FIRST INCIDENCE	589	484	678	554

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.299	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.283	P=0.002**	P<0.001**
POLY 6	P<0.001**	P=0.321	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.262	P=0.003**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.206	P<0.001**	P<0.001**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Respiratory Epithelium  
Necrosis**

**LESION RATES**

OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	8/50 (16%)
POLY-3 RATE (b)	2/43.77	3/46.58	3/43.29	8/46.18
POLY-3 PERCENT (g)	4.6%	6.4%	6.9%	17.3%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	2/32 (6%)	5/37 (14%)
FIRST INCIDENCE	589	484	705	563

**STATISTICAL TESTS**

POLY 3	P=0.018*	P=0.528	P=0.495	P=0.054
POLY 1.5	P=0.017*	P=0.516	P=0.496	P=0.050*
POLY 6	P=0.019*	P=0.544	P=0.494	P=0.060
COCH-ARM / FISHERS	P=0.017*	P=0.500	P=0.500	P=0.046*
MAX-ISO-POLY-3	P=0.027*	P=0.353	P=0.320	P=0.029*

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Respiratory Epithelium  
Ulcer**

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	1/43.30	1/46.46	2/43.32	4/45.59
POLY-3 PERCENT (g)	2.3%	2.2%	4.6%	8.8%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	3/37 (8%)
FIRST INCIDENCE	606	484	705	659

**STATISTICAL TESTS**

POLY 3	P=0.075	P=0.745N	P=0.500	P=0.194
POLY 1.5	P=0.074	P=0.752N	P=0.499	P=0.187
POLY 6	P=0.078	P=0.736N	P=0.502	P=0.205
COCH-ARM / FISHERS	P=0.072	P=0.753N	P=0.500	P=0.181
MAX-ISO-POLY-3	P=0.115	P=0.480N	P=0.280	P=0.098

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Respiratory Epithelium  
Vacuolization Cytoplasmic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.93	3/43.78	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	6.9%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	---	684	618	---

**STATISTICAL TESTS**

POLY 3	P=0.610N	P=0.514	P=0.122	(e)
POLY 1.5	P=0.620N	P=0.508	P=0.120	(e)
POLY 6	P=0.596N	P=0.523	P=0.126	(e)
COCH-ARM / FISHERS	P=0.631N	P=0.500	P=0.121	(e)
MAX-ISO-POLY-3	P=0.240	P=0.175	P=0.041*	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Turbinate  
Hyperostosis**

**LESION RATES**

OVERALL (a)	5/50 (10%)	23/50 (46%)	50/50 (100%)	50/50 (100%)
POLY-3 RATE (b)	5/43.35	23/47.89	50/50.00	50/50.00
POLY-3 PERCENT (g)	11.5%	48%	100%	100%
TERMINAL (d)	3/31 (10%)	17/38 (45%)	32/32 (100%)	37/37 (100%)
FIRST INCIDENCE	620	484	442	442

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Turbinate  
Necrosis**

**LESION RATES**

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	1/43.30	0/45.75	0/43.20	3/45.59
POLY-3 PERCENT (g)	2.3%	0%	0%	6.6%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	2/37 (5%)
FIRST INCIDENCE	606	---	---	659

**STATISTICAL TESTS**

POLY 3	P=0.084	P=0.489N	P=0.500N	P=0.324
POLY 1.5	P=0.085	P=0.494N	P=0.501N	P=0.315
POLY 6	P=0.084	P=0.482N	P=0.500N	P=0.336
COCH-ARM / FISHERS	P=0.086	P=0.500N	P=0.500N	P=0.309
MAX-ISO-POLY-3	P=0.053	P=0.158N	P=0.159N	P=0.173

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Pancreas  
Atrophy**

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.29	1/45.80	1/42.79	0/45.33
POLY-3 PERCENT (g)	2.3%	2.2%	2.3%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	609	718	723	---

**STATISTICAL TESTS**

POLY 3	P=0.308N	P=0.748N	P=0.758	P=0.491N
POLY 1.5	P=0.311N	P=0.754N	P=0.757	P=0.495N
POLY 6	P=0.304N	P=0.740N	P=0.761	P=0.485N
COCH-ARM / FISHERS	P=0.313N	P=0.753N	P=0.747	P=0.500N
MAX-ISO-POLY-3	P=0.335N	P=0.484N	P=0.496	P=0.158N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Pancreas  
Cyst**

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.09	1/45.80	0/42.77	0/45.33
POLY-3 PERCENT (g)	2.3%	2.2%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	673	718	---	---

**STATISTICAL TESTS**

POLY 3	P=0.239N	P=0.747N	P=0.501N	P=0.490N
POLY 1.5	P=0.240N	P=0.753N	P=0.503N	P=0.494N
POLY 6	P=0.238N	P=0.738N	P=0.499N	P=0.483N
COCH-ARM / FISHERS	P=0.240N	P=0.753N	P=0.505N	P=0.500N
MAX-ISO-POLY-3	P=0.256N	P=0.482N	P=0.160N	P=0.158N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Parathyroid Gland  
Cyst**

**LESION RATES**

OVERALL (a)	0/28 (0%)	1/32 (3%)	1/25 (4%)	0/21 (0%)
POLY-3 RATE (b)	0/23.59	1/30.00	1/21.67	0/18.31
POLY-3 PERCENT (g)	0%	3.3%	4.6%	0%
TERMINAL (d)	0/17 (0%)	0/26 (0%)	0/17 (0%)	0/15 (0%)
FIRST INCIDENCE	---	484	609	---

**STATISTICAL TESTS**

POLY 3	P=0.665N	P=0.548	P=0.483	(e)
POLY 1.5	P=0.668N	P=0.538	P=0.480	(e)
POLY 6	P=0.658N	P=0.561	P=0.490	(e)
COCH-ARM / FISHERS	P=0.673N	P=0.533	P=0.472	(e)
MAX-ISO-POLY-3	P=0.447	P=0.208	P=0.150	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Penis  
Inflammation**

**LESION RATES**

OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/2 (100%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	2/2.00
POLY-3 PERCENT (g)	0%	0%	0%	100%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	659

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis  
Angiectasis**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/42.59	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Pituitary Gland: Pars Distalis  
Cyst**

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	3/49 (6%)	2/50 (4%)
POLY-3 RATE (b)	1/42.87	2/45.75	3/42.61	2/45.33
POLY-3 PERCENT (g)	2.3%	4.4%	7%	4.4%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	2/32 (6%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	723	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.429	P=0.523	P=0.303	P=0.519
POLY 1.5	P=0.418	P=0.513	P=0.300	P=0.511
POLY 6	P=0.445	P=0.537	P=0.308	P=0.532
COCH-ARM / FISHERS	P=0.405	P=0.500	P=0.301	P=0.500
MAX-ISO-POLY-3	P=0.376	P=0.305	P=0.152	P=0.302

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Pituitary Gland: Pars Distalis  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	7/50 (14%)	2/49 (4%)	6/50 (12%)
POLY-3 RATE (b)	0/42.87	7/45.80	2/42.59	6/45.33
POLY-3 PERCENT (g)	0%	15.3%	4.7%	13.2%
TERMINAL (d)	0/31 (0%)	6/38 (16%)	2/32 (6%)	6/37 (16%)
FIRST INCIDENCE	---	718	729 (T)	729 (T)

**STATISTICAL TESTS**

POLY 3	P=0.087	P=0.010**	P=0.235	P=0.018*
POLY 1.5	P=0.081	P=0.009**	P=0.234	P=0.017*
POLY 6	P=0.097	P=0.011*	P=0.239	P=0.020*
COCH-ARM / FISHERS	P=0.077	P=0.006**	P=0.242	P=0.013*
MAX-ISO-POLY-3	P=0.021*	P=0.004**	P=0.075	P=0.007**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Preputial Gland  
Ectasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	2/45.43
POLY-3 PERCENT (g)	0%	0%	0%	4.4%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	715

**STATISTICAL TESTS**

POLY 3	P=0.046*	(e)	(e)	P=0.250
POLY 1.5	P=0.046*	(e)	(e)	P=0.244
POLY 6	P=0.047*	(e)	(e)	P=0.259
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.043*	(e)	(e)	P=0.089

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Preputial Gland  
Inflammation**

**LESION RATES**

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/42.87	1/45.75	1/43.39	0/45.33
POLY-3 PERCENT (g)	4.7%	2.2%	2.3%	0%
TERMINAL (d)	2/31 (7%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	678	---

**STATISTICAL TESTS**

POLY 3	P=0.151N	P=0.477N	P=0.496N	P=0.225N
POLY 1.5	P=0.152N	P=0.487N	P=0.498N	P=0.230N
POLY 6	P=0.149N	P=0.463N	P=0.491N	P=0.217N
COCH-ARM / FISHERS	P=0.153N	P=0.500N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.121N	P=0.268N	P=0.278N	P=0.076N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Seminal Vesicle  
Dilatation**

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/42.87	2/45.93	1/43.20	0/45.33
POLY-3 PERCENT (g)	2.3%	4.4%	2.3%	0%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	684	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.238N	P=0.524	P=0.759N	P=0.489N
POLY 1.5	P=0.244N	P=0.513	P=0.760N	P=0.494N
POLY 6	P=0.230N	P=0.540	P=0.757N	P=0.482N
COCH-ARM / FISHERS	P=0.250N	P=0.500	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.243N	P=0.306	P=0.497N	P=0.158N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Skin  
Inflammation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/49 (0%)	3/50 (6%)
POLY-3 RATE (b)	0/42.87	1/45.80	0/42.20	3/45.78
POLY-3 PERCENT (g)	0%	2.2%	0%	6.6%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/31 (0%)	1/37 (3%)
FIRST INCIDENCE	---	718	---	659

**STATISTICAL TESTS**

POLY 3	P=0.045*	P=0.513	(e)	P=0.131
POLY 1.5	P=0.044*	P=0.507	(e)	P=0.125
POLY 6	P=0.048*	P=0.522	(e)	P=0.140
COCH-ARM / FISHERS	P=0.043*	P=0.500	(e)	P=0.121
MAX-ISO-POLY-3	P=0.033*	P=0.175	(e)	P=0.048*

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Skin  
Ulcer**

**LESION RATES**

OVERALL (a)	1/50 (2%)	3/50 (6%)	5/49 (10%)	3/50 (6%)
POLY-3 RATE (b)	1/43.36	3/45.83	5/43.05	3/46.13
POLY-3 PERCENT (g)	2.3%	6.6%	11.6%	6.5%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	3/31 (10%)	0/37 (0%)
FIRST INCIDENCE	584	710	508	554

**STATISTICAL TESTS**

POLY 3	P=0.307	P=0.325	P=0.099	P=0.328
POLY 1.5	P=0.293	P=0.316	P=0.098	P=0.318
POLY 6	P=0.330	P=0.339	P=0.101	P=0.343
COCH-ARM / FISHERS	P=0.275	P=0.309	P=0.098	P=0.309
MAX-ISO-POLY-3	P=0.177	P=0.175	P=0.043*	P=0.177

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Spleen  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	3/49 (6%)	2/50 (4%)
POLY-3 RATE (b)	0/42.87	2/45.75	3/43.16	2/45.57
POLY-3 PERCENT (g)	0%	4.4%	7%	4.4%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	2/32 (6%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	618	680

**STATISTICAL TESTS**

POLY 3	P=0.264	P=0.252	P=0.119	P=0.251
POLY 1.5	P=0.252	P=0.245	P=0.117	P=0.245
POLY 6	P=0.282	P=0.262	P=0.123	P=0.261
COCH-ARM / FISHERS	P=0.238	P=0.247	P=0.117	P=0.247
MAX-ISO-POLY-3	P=0.150	P=0.090	P=0.039*	P=0.089

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Spleen  
Hyperplasia Lymphoid**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/42.77	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Stomach, Forestomach  
Hyperplasia**

**LESION RATES**

OVERALL (a)	3/50 (6%)	4/50 (8%)	6/50 (12%)	4/50 (8%)
POLY-3 RATE (b)	3/44.15	4/45.75	6/44.00	4/45.93
POLY-3 PERCENT (g)	6.8%	8.7%	13.6%	8.7%
TERMINAL (d)	0/31 (0%)	4/38 (11%)	4/32 (13%)	2/37 (5%)
FIRST INCIDENCE	589	729 (T)	609	555

**STATISTICAL TESTS**

POLY 3	P=0.442	P=0.519	P=0.239	P=0.522
POLY 1.5	P=0.431	P=0.511	P=0.240	P=0.512
POLY 6	P=0.456	P=0.531	P=0.240	P=0.535
COCH-ARM / FISHERS	P=0.418	P=0.500	P=0.243	P=0.500
MAX-ISO-POLY-3	P=0.398	P=0.367	P=0.145	P=0.369

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Stomach, Forestomach  
Inflammation**

**LESION RATES**

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.68	2/46.65	0/43.20	0/45.33
POLY-3 PERCENT (g)	4.6%	4.3%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	609	536	---	---

**STATISTICAL TESTS**

POLY 3	P=0.087N	P=0.670N	P=0.239N	P=0.229N
POLY 1.5	P=0.087N	P=0.680N	P=0.239N	P=0.233N
POLY 6	P=0.086N	P=0.656N	P=0.240N	P=0.224N
COCH-ARM / FISHERS	P=0.088N	P=0.691N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.120N	P=0.473N	P=0.078N	P=0.076N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Glandular  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	3/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	7%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	3/32 (9%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.575	(e)	P=0.120	(e)
POLY 1.5	P=0.564	(e)	P=0.119	(e)
POLY 6	P=0.590	(e)	P=0.121	(e)
COCH-ARM / FISHERS	P=0.549	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.178	(e)	P=0.039*	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Testes  
Degeneration**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	2/45.75	1/43.22	0/45.33
POLY-3 PERCENT (g)	0%	4.4%	2.3%	0%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	723	---

**STATISTICAL TESTS**

POLY 3	P=0.444N	P=0.252	P=0.502	(e)
POLY 1.5	P=0.454N	P=0.245	P=0.501	(e)
POLY 6	P=0.429N	P=0.262	P=0.504	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.341N	P=0.090	P=0.161	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Thymus  
Cyst**

**LESION RATES**

OVERALL (a)	1/38 (3%)	0/36 (0%)	2/36 (6%)	2/37 (5%)
POLY-3 RATE (b)	1/33.33	0/33.70	2/31.94	2/35.01
POLY-3 PERCENT (g)	3%	0%	6.3%	5.7%
TERMINAL (d)	1/26 (4%)	0/29 (0%)	2/25 (8%)	1/30 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	554

**STATISTICAL TESTS**

POLY 3	P=0.263	P=0.498N	P=0.485	P=0.517
POLY 1.5	P=0.256	P=0.503N	P=0.483	P=0.506
POLY 6	P=0.272	P=0.491N	P=0.489	P=0.532
COCH-ARM / FISHERS	P=0.246	P=0.514N	P=0.479	P=0.490
MAX-ISO-POLY-3	P=0.279	P=0.162N	P=0.269	P=0.300

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Thyroid Gland  
Cyst**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/48 (4%)	1/49 (2%)
POLY-3 RATE (b)	0/42.87	1/45.75	2/42.10	1/44.89
POLY-3 PERCENT (g)	0%	2.2%	4.8%	2.2%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	1/31 (3%)	0/36 (0%)
FIRST INCIDENCE	---	729 (T)	506	554

**STATISTICAL TESTS**

POLY 3	P=0.390	P=0.513	P=0.233	P=0.509
POLY 1.5	P=0.378	P=0.507	P=0.230	P=0.503
POLY 6	P=0.407	P=0.521	P=0.237	P=0.518
COCH-ARM / FISHERS	P=0.362	P=0.500	P=0.237	P=0.495
MAX-ISO-POLY-3	P=0.238	P=0.174	P=0.074	P=0.171

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Thyroid Gland: Follicular Cell  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/48 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/41.44	0/44.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/31 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Tooth: Dentine Malformation**

**LESION RATES**

OVERALL (a)	4/6 (67%)	2/6 (33%)	5/8 (63%)	5/5 (100%)
POLY-3 RATE (b)	4/5.62	2/5.51	5/7.98	5/5.00
POLY-3 PERCENT (g)	71.2%	36.3%	62.7%	100%
TERMINAL (d)	4/5 (80%)	1/3 (33%)	3/5 (60%)	4/4 (100%)
FIRST INCIDENCE	729 (T)	684	678	555

**STATISTICAL TESTS**

POLY 3	P=0.126	P=0.285N	P=0.595N	P=0.317
POLY 1.5	P=0.114	P=0.286N	P=0.618N	P=0.287
POLY 6	P=0.150	P=0.286N	P=0.559N	P=0.374
COCH-ARM / FISHERS	P=0.109	P=0.284N	P=0.657N	P=0.273
MAX-ISO-POLY-3	P=0.076	P=0.123N	P=0.387N	P=0.085

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Cortex  
Accessory Adrenal Cortical Nodule**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	2/43.50	0/43.30	3/47.62	1/47.37
POLY-3 PERCENT (g)	4.6%	0%	6.3%	2.1%
TERMINAL (d)	2/32 (6%)	0/35 (0%)	2/36 (6%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	---	722	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.513N	P=0.238N	P=0.541	P=0.470N
POLY 1.5	P=0.526N	P=0.237N	P=0.527	P=0.479N
POLY 6	P=0.499N	P=0.239N	P=0.558	P=0.461N
COCH-ARM / FISHERS	P=0.550N	P=0.247N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.423N	P=0.077N	P=0.367	P=0.264N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Cortex  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	2/43.97	1/47.59	0/47.37
POLY-3 PERCENT (g)	0%	4.6%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	---	627	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.435N	P=0.239	P=0.518	(e)
POLY 1.5	P=0.444N	P=0.239	P=0.512	(e)
POLY 6	P=0.425N	P=0.241	P=0.525	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.334N	P=0.078	P=0.180	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex  
Hyperplasia**

**LESION RATES**

OVERALL (a)	5/50 (10%)	3/50 (6%)	8/50 (16%)	7/50 (14%)
POLY-3 RATE (b)	5/43.50	3/43.30	8/47.59	7/47.37
POLY-3 PERCENT (g)	11.5%	6.9%	16.8%	14.8%
TERMINAL (d)	5/32 (16%)	3/35 (9%)	8/36 (22%)	7/39 (18%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.258	P=0.358N	P=0.336	P=0.440
POLY 1.5	P=0.237	P=0.355N	P=0.316	P=0.421
POLY 6	P=0.281	P=0.361N	P=0.362	P=0.461
COCH-ARM / FISHERS	P=0.198	P=0.357N	P=0.277	P=0.380
MAX-ISO-POLY-3	P=0.295	P=0.233N	P=0.245	P=0.329

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex  
Hypertrophy**

**LESION RATES**

OVERALL (a)	10/50 (20%)	13/50 (26%)	7/50 (14%)	8/50 (16%)
POLY-3 RATE (b)	10/44.49	13/43.30	7/47.59	8/47.37
POLY-3 PERCENT (g)	22.5%	30%	14.7%	16.9%
TERMINAL (d)	6/32 (19%)	13/35 (37%)	7/36 (19%)	8/39 (21%)
FIRST INCIDENCE	533	731 (T)	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.163N	P=0.287	P=0.245N	P=0.341N
POLY 1.5	P=0.179N	P=0.305	P=0.261N	P=0.356N
POLY 6	P=0.149N	P=0.265	P=0.228N	P=0.328N
COCH-ARM / FISHERS	P=0.218N	P=0.318	P=0.298N	P=0.398N
MAX-ISO-POLY-3	P=0.183N	P=0.213	P=0.177N	P=0.257N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Cortex  
Vacuolization Cytoplasmic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	3/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	6.3%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	0/39 (0%)
FIRST INCIDENCE	---	---	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.603	(e)	P=0.136	(e)
POLY 1.5	P=0.586	(e)	P=0.130	(e)
POLY 6	P=0.622	(e)	P=0.143	(e)
COCH-ARM / FISHERS	P=0.549	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.201	(e)	P=0.052	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Adrenal Medulla  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	3/49 (6%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	3/46.37
POLY-3 PERCENT (g)	0%	0%	0%	6.5%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	3/38 (8%)
FIRST INCIDENCE	---	---	---	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.012*	(e)	(e)	P=0.131
POLY 1.5	P=0.011*	(e)	(e)	P=0.126
POLY 6	P=0.012*	(e)	(e)	P=0.136
COCH-ARM / FISHERS	P=0.011*	(e)	(e)	P=0.117
MAX-ISO-POLY-3	P=0.014*	(e)	(e)	P=0.049*

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Brain  
Atrophy**

**LESION RATES**

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/44.14	1/43.30	1/47.59	0/47.37
POLY-3 PERCENT (g)	4.5%	2.3%	2.1%	0%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	592	731 (T)	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.142N	P=0.507N	P=0.474N	P=0.222N
POLY 1.5	P=0.146N	P=0.502N	P=0.482N	P=0.226N
POLY 6	P=0.138N	P=0.512N	P=0.464N	P=0.218N
COCH-ARM / FISHERS	P=0.153N	P=0.500N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.121N	P=0.288N	P=0.266N	P=0.076N

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Eye  
Cataract**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	1/47.81	0/47.37
POLY-3 PERCENT (g)	0%	0%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	673	---

**STATISTICAL TESTS**

POLY 3	P=0.732	(e)	P=0.519	(e)
POLY 1.5	P=0.722	(e)	P=0.512	(e)
POLY 6	P=0.743	(e)	P=0.527	(e)
COCH-ARM / FISHERS	P=0.701	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.417	(e)	P=0.182	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

Eye: Cornea  
Inflammation Chronic

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/43.52	0/43.30	0/47.59	1/47.37
POLY-3 PERCENT (g)	4.6%	0%	0%	2.1%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	726	---	---	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.456N	P=0.238N	P=0.218N	P=0.471N
POLY 1.5	P=0.459N	P=0.237N	P=0.224N	P=0.480N
POLY 6	P=0.454N	P=0.239N	P=0.210N	P=0.461N
COCH-ARM / FISHERS	P=0.461N	P=0.247N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.130N	P=0.077N	P=0.076N	P=0.264N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Harderian Gland  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	1/43.30	2/47.59	0/47.37
POLY-3 PERCENT (g)	0%	2.3%	4.2%	0%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	2/36 (6%)	0/39 (0%)
FIRST INCIDENCE	---	731 (T)	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.580N	P=0.499	P=0.258	(e)
POLY 1.5	P=0.591N	P=0.500	P=0.251	(e)
POLY 6	P=0.568N	P=0.498	P=0.267	(e)
COCH-ARM / FISHERS	P=0.615N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.343N	P=0.158	P=0.096	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Heart  
Cardiomyopathy**

**LESION RATES**

OVERALL (a)	5/50 (10%)	2/50 (4%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	5/43.80	2/43.30	3/47.59	1/47.37
POLY-3 PERCENT (g)	11.4%	4.6%	6.3%	2.1%
TERMINAL (d)	4/32 (13%)	2/35 (6%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	649	731 (T)	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.077N	P=0.220N	P=0.312N	P=0.084N
POLY 1.5	P=0.082N	P=0.217N	P=0.326N	P=0.089N
POLY 6	P=0.071N	P=0.224N	P=0.295N	P=0.080N
COCH-ARM / FISHERS	P=0.094N	P=0.218N	P=0.357N	P=0.102N
MAX-ISO-POLY-3	P=0.056N	P=0.123N	P=0.205N	P=0.041N*

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Heart: Artery  
Inflammation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	2/43.52	0/47.59	1/47.41
POLY-3 PERCENT (g)	0%	4.6%	0%	2.1%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	673	---	719

**STATISTICAL TESTS**

POLY 3	P=0.565	P=0.237	(e)	P=0.517
POLY 1.5	P=0.556	P=0.238	(e)	P=0.512
POLY 6	P=0.575	P=0.237	(e)	P=0.523
COCH-ARM / FISHERS	P=0.534	P=0.247	(e)	P=0.500
MAX-ISO-POLY-3	P=0.355	P=0.076	(e)	P=0.180

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

Heart: Atrium  
Thrombosis

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Heart: Capillary  
Hyperplasia**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.29	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	584	---	---	---

**STATISTICAL TESTS**

POLY 3	P=0.111N	P=0.242N	P=0.222N	P=0.223N
POLY 1.5	P=0.113N	P=0.239N	P=0.226N	P=0.226N
POLY 6	P=0.110N	P=0.246N	P=0.216N	P=0.219N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.081N	P=0.076N	P=0.076N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Intestine Small, Ileum  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	1/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	---	---	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.732	(e)	P=0.518	(e)
POLY 1.5	P=0.722	(e)	P=0.512	(e)
POLY 6	P=0.744	(e)	P=0.525	(e)
COCH-ARM / FISHERS	P=0.701	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.416	(e)	P=0.180	(e)

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Islets, Pancreatic  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	1/47.37
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	---	---	---	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.213	(e)	(e)	P=0.517
POLY 1.5	P=0.209	(e)	(e)	P=0.512
POLY 6	P=0.218	(e)	(e)	P=0.523
COCH-ARM / FISHERS	P=0.200	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.153	(e)	(e)	P=0.179

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney  
Cyst**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	1/43.60	1/47.59	0/47.37
POLY-3 PERCENT (g)	0%	2.3%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	---	649	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.573N	P=0.500	P=0.518	(e)
POLY 1.5	P=0.580N	P=0.501	P=0.512	(e)
POLY 6	P=0.565N	P=0.501	P=0.525	(e)
COCH-ARM / FISHERS	P=0.597N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.417N	P=0.159	P=0.180	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney  
Infarct**

**LESION RATES**

OVERALL (a)	2/50 (4%)	2/50 (4%)	4/50 (8%)	6/50 (12%)
POLY-3 RATE (b)	2/43.50	2/43.30	4/47.59	6/47.47
POLY-3 PERCENT (g)	4.6%	4.6%	8.4%	12.6%
TERMINAL (d)	2/32 (6%)	2/35 (6%)	4/36 (11%)	5/39 (13%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	704

**STATISTICAL TESTS**

POLY 3	P=0.075	P=0.693	P=0.380	P=0.163
POLY 1.5	P=0.068	P=0.693N	P=0.365	P=0.154
POLY 6	P=0.082	P=0.691	P=0.397	P=0.174
COCH-ARM / FISHERS	P=0.056	P=0.691N	P=0.339	P=0.134
MAX-ISO-POLY-3	P=0.117	P=0.497	P=0.244	P=0.097

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney  
Metaplasia Osseous**

**LESION RATES**

OVERALL (a)	8/50 (16%)	3/50 (6%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	8/43.80	3/43.52	1/47.59	4/47.65
POLY-3 PERCENT (g)	18.3%	6.9%	2.1%	8.4%
TERMINAL (d)	7/32 (22%)	2/35 (6%)	1/36 (3%)	3/39 (8%)
FIRST INCIDENCE	649	673	731 (T)	653

**STATISTICAL TESTS**

POLY 3	P=0.122N	P=0.099N	P=0.011N*	P=0.138N
POLY 1.5	P=0.129N	P=0.097N	P=0.012N*	P=0.150N
POLY 6	P=0.115N	P=0.100N	P=0.009N**	P=0.126N
COCH-ARM / FISHERS	P=0.146N	P=0.100N	P=0.015N*	P=0.178N
MAX-ISO-POLY-3	P=0.024N*	P=0.053N	P=0.005N**	P=0.090N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Kidney  
Nephropathy**

**LESION RATES**

OVERALL (a)	39/50 (78%)	40/50 (80%)	43/50 (86%)	46/50 (92%)
POLY-3 RATE (b)	39/46.98	40/45.82	43/48.62	46/50.00
POLY-3 PERCENT (g)	83%	87.3%	88.5%	92%
TERMINAL (d)	28/32 (88%)	34/35 (97%)	33/36 (92%)	35/39 (90%)
FIRST INCIDENCE	522	533	673	610

**STATISTICAL TESTS**

POLY 3	P=0.107	P=0.377	P=0.313	P=0.143
POLY 1.5	P=0.068	P=0.459	P=0.294	P=0.104
POLY 6	P=0.182	P=0.266	P=0.336	P=0.202
COCH-ARM / FISHERS	P=0.025*	P=0.500	P=0.218	P=0.045*
MAX-ISO-POLY-3	P=0.127	P=0.267	P=0.218	P=0.089

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Larynx  
Hyperplasia**

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	1/43.50	2/43.30	1/47.64	3/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	2.1%	6.3%
TERMINAL (d)	1/32 (3%)	2/35 (6%)	0/36 (0%)	3/39 (8%)
FIRST INCIDENCE	731 (T)	731 (T)	718	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.267	P=0.498	P=0.740N	P=0.336
POLY 1.5	P=0.257	P=0.501	P=0.747N	P=0.327
POLY 6	P=0.278	P=0.496	P=0.731N	P=0.347
COCH-ARM / FISHERS	P=0.236	P=0.500	P=0.753N	P=0.309
MAX-ISO-POLY-3	P=0.275	P=0.279	P=0.474N	P=0.186

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Basophilic Focus**

**LESION RATES**

OVERALL (a)	1/50 (2%)	3/50 (6%)	6/50 (12%)	1/50 (2%)
POLY-3 RATE (b)	1/43.50	3/43.30	6/47.62	1/47.37
POLY-3 PERCENT (g)	2.3%	6.9%	12.6%	2.1%
TERMINAL (d)	1/32 (3%)	3/35 (9%)	5/36 (14%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	731 (T)	722	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.491N	P=0.303	P=0.072	P=0.741N
POLY 1.5	P=0.513N	P=0.306	P=0.067	P=0.747N
POLY 6	P=0.468N	P=0.301	P=0.079	P=0.735N
COCH-ARM / FISHERS	P=0.559N	P=0.309	P=0.056	P=0.753N
MAX-ISO-POLY-3	P=0.245N	P=0.153	P=0.037*	P=0.476N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

Liver  
Clear Cell Focus

**LESION RATES**

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.50	0/43.30	2/47.81	0/47.37
POLY-3 PERCENT (g)	2.3%	0%	4.2%	0%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	---	673	---

**STATISTICAL TESTS**

POLY 3	P=0.427N	P=0.501N	P=0.533	P=0.483N
POLY 1.5	P=0.437N	P=0.500N	P=0.522	P=0.488N
POLY 6	P=0.417N	P=0.502N	P=0.547	P=0.477N
COCH-ARM / FISHERS	P=0.456N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.332N	P=0.160N	P=0.316	P=0.158N

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Congestion**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver  
Cyst

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.50	2/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	0%	0%
TERMINAL (d)	1/32 (3%)	2/35 (6%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	---	---

**STATISTICAL TESTS**

POLY 3	P=0.181N	P=0.498	P=0.482N	P=0.483N
POLY 1.5	P=0.184N	P=0.501	P=0.488N	P=0.488N
POLY 6	P=0.178N	P=0.496	P=0.475N	P=0.477N
COCH-ARM / FISHERS	P=0.193N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.171N	P=0.279	P=0.158N	P=0.158N

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver  
 Degeneration Fatty

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.50	1/43.67	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	2.3%	0%	0%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	627	---	---

**STATISTICAL TESTS**

POLY 3	P=0.233N	P=0.760N	P=0.482N	P=0.483N
POLY 1.5	P=0.235N	P=0.759N	P=0.488N	P=0.488N
POLY 6	P=0.231N	P=0.760N	P=0.475N	P=0.477N
COCH-ARM / FISHERS	P=0.239N	P=0.753N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.255N	P=0.498N	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Eosinophilic Focus**

**LESION RATES**

OVERALL (a)	4/50 (8%)	7/50 (14%)	8/50 (16%)	2/50 (4%)
POLY-3 RATE (b)	4/43.50	7/43.30	8/47.64	2/47.37
POLY-3 PERCENT (g)	9.2%	16.2%	16.8%	4.2%
TERMINAL (d)	4/32 (13%)	7/35 (20%)	7/36 (19%)	2/39 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	718	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.167N	P=0.257	P=0.224	P=0.299N
POLY 1.5	P=0.186N	P=0.262	P=0.208	P=0.311N
POLY 6	P=0.148N	P=0.252	P=0.245	P=0.286N
COCH-ARM / FISHERS	P=0.229N	P=0.262	P=0.178	P=0.339N
MAX-ISO-POLY-3	P=0.121N	P=0.165	P=0.153	P=0.181N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/44.29	2/43.97	0/47.59	1/47.37
POLY-3 PERCENT (g)	4.5%	4.6%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	584	627	---	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.287N	P=0.691	P=0.222N	P=0.477N
POLY 1.5	P=0.291N	P=0.694N	P=0.226N	P=0.483N
POLY 6	P=0.284N	P=0.690	P=0.216N	P=0.471N
COCH-ARM / FISHERS	P=0.300N	P=0.691N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.262N	P=0.496	P=0.076N	P=0.268N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Mixed Cell Focus**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	0/43.50	0/43.30	2/47.59	2/47.47
POLY-3 PERCENT (g)	0%	0%	4.2%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	2/36 (6%)	1/39 (3%)
FIRST INCIDENCE	---	---	731 (T)	704

**STATISTICAL TESTS**

POLY 3	P=0.106	(e)	P=0.258	P=0.257
POLY 1.5	P=0.099	(e)	P=0.251	P=0.251
POLY 6	P=0.113	(e)	P=0.267	P=0.264
COCH-ARM / FISHERS	P=0.088	(e)	P=0.247	P=0.247
MAX-ISO-POLY-3	P=0.150	(e)	P=0.096	P=0.095

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver  
Necrosis

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	1/44.14	2/43.51	3/47.91	3/48.34
POLY-3 PERCENT (g)	2.3%	4.6%	6.3%	6.2%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	522	676	690	626

**STATISTICAL TESTS**

POLY 3	P=0.275	P=0.495	P=0.335	P=0.339
POLY 1.5	P=0.259	P=0.499	P=0.325	P=0.328
POLY 6	P=0.295	P=0.492	P=0.349	P=0.352
COCH-ARM / FISHERS	P=0.228	P=0.500	P=0.309	P=0.309
MAX-ISO-POLY-3	P=0.324	P=0.278	P=0.185	P=0.188

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Tension Lipidosis**

**LESION RATES**

OVERALL (a)	5/50 (10%)	8/50 (16%)	3/50 (6%)	9/50 (18%)
POLY-3 RATE (b)	5/43.76	8/44.07	3/47.86	9/47.64
POLY-3 PERCENT (g)	11.4%	18.2%	6.3%	18.9%
TERMINAL (d)	3/32 (9%)	6/35 (17%)	2/36 (6%)	8/39 (21%)
FIRST INCIDENCE	690	564	659	656

**STATISTICAL TESTS**

POLY 3	P=0.271	P=0.279	P=0.309N	P=0.243
POLY 1.5	P=0.254	P=0.281	P=0.325N	P=0.227
POLY 6	P=0.288	P=0.277	P=0.290N	P=0.259
COCH-ARM / FISHERS	P=0.220	P=0.277	P=0.357N	P=0.194
MAX-ISO-POLY-3	P=0.256	P=0.188	P=0.203N	P=0.172

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung  
Hemorrhage**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	1/43.51	0/47.59	1/47.37
POLY-3 PERCENT (g)	0%	2.3%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	---	676	---	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.427	P=0.500	(e)	P=0.517
POLY 1.5	P=0.420	P=0.501	(e)	P=0.512
POLY 6	P=0.435	P=0.500	(e)	P=0.523
COCH-ARM / FISHERS	P=0.403	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.289	P=0.159	(e)	P=0.179

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung  
Infiltration Cellular Histiocyte**

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	1/43.64	2/44.53	3/47.59	1/47.37
POLY-3 PERCENT (g)	2.3%	4.5%	6.3%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	695	444	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.535N	P=0.507	P=0.337	P=0.742N
POLY 1.5	P=0.548N	P=0.506	P=0.327	P=0.748N
POLY 6	P=0.522N	P=0.508	P=0.350	P=0.736N
COCH-ARM / FISHERS	P=0.577N	P=0.500	P=0.309	P=0.753N
MAX-ISO-POLY-3	P=0.469N	P=0.288	P=0.187	P=0.477N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung: Alveolar Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	1/43.30	3/47.59	1/47.37
POLY-3 PERCENT (g)	0%	2.3%	6.3%	2.1%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	---	731 (T)	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.406	P=0.499	P=0.136	P=0.517
POLY 1.5	P=0.390	P=0.500	P=0.130	P=0.512
POLY 6	P=0.424	P=0.498	P=0.143	P=0.523
COCH-ARM / FISHERS	P=0.355	P=0.500	P=0.121	P=0.500
MAX-ISO-POLY-3	P=0.191	P=0.158	P=0.052	P=0.179

---

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung: Arteriole  
 Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	1/47.41
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	719

**STATISTICAL TESTS**

POLY 3	P=0.213	(e)	(e)	P=0.517
POLY 1.5	P=0.209	(e)	(e)	P=0.512
POLY 6	P=0.218	(e)	(e)	P=0.523
COCH-ARM / FISHERS	P=0.200	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.154	(e)	(e)	P=0.180

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lymph Node, Mandibular  
Hyperplasia Lymphoid**

**LESION RATES**

OVERALL (a)	2/23 (9%)	0/40 (0%)	0/30 (0%)	1/33 (3%)
POLY-3 RATE (b)	2/19.81	0/34.35	0/28.96	1/31.51
POLY-3 PERCENT (g)	10.1%	0%	0%	3.2%
TERMINAL (d)	0/11 (0%)	0/28 (0%)	0/21 (0%)	0/26 (0%)
FIRST INCIDENCE	584	---	---	635

**STATISTICAL TESTS**

POLY 3	P=0.412N	P=0.122N	P=0.156N	P=0.341N
POLY 1.5	P=0.416N	P=0.120N	P=0.161N	P=0.349N
POLY 6	P=0.411N	P=0.122N	P=0.150N	P=0.331N
COCH-ARM / FISHERS	P=0.415N	P=0.130N	P=0.184N	P=0.365N
MAX-ISO-POLY-3	P=0.062N	P=0.043N*	P=0.058N	P=0.186N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lymph Node, Mesenteric  
Infiltration Cellular**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/46 (0%)	0/46 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.50	0/40.48	0/43.75	0/46.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/34 (0%)	0/33 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Mesentery  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/12 (0%)	1/16 (6%)	0/15 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/11.77	1/15.29	0/14.28	0/8.85
POLY-3 PERCENT (g)	0%	6.5%	0%	0%
TERMINAL (d)	0/9 (0%)	0/13 (0%)	0/8 (0%)	0/6 (0%)
FIRST INCIDENCE	---	627	---	---

**STATISTICAL TESTS**

POLY 3	P=0.621N	P=0.552	(e)	(e)
POLY 1.5	P=0.620N	P=0.554	(e)	(e)
POLY 6	P=0.623N	P=0.550	(e)	(e)
COCH-ARM / FISHERS	P=0.620N	P=0.571	(e)	(e)
MAX-ISO-POLY-3	P=0.477N	P=0.204	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Mesentery: Fat  
Necrosis**

**LESION RATES**

OVERALL (a)	10/12 (83%)	12/16 (75%)	11/15 (73%)	6/10 (60%)
POLY-3 RATE (b)	10/11.88	12/15.59	11/14.77	6/9.22
POLY-3 PERCENT (g)	84.2%	77%	74.5%	65.1%
TERMINAL (d)	9/9 (100%)	10/13 (77%)	6/8 (75%)	5/6 (83%)
FIRST INCIDENCE	704	627	680	626

**STATISTICAL TESTS**

POLY 3	P=0.218N	P=0.505N	P=0.448N	P=0.301N
POLY 1.5	P=0.192N	P=0.492N	P=0.444N	P=0.266N
POLY 6	P=0.270N	P=0.518N	P=0.455N	P=0.372N
COCH-ARM / FISHERS	P=0.161N	P=0.479N	P=0.443N	P=0.229N
MAX-ISO-POLY-3	P=0.279N	P=0.329N	P=0.283N	P=0.166N



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose  
Inflammation**

**LESION RATES**

OVERALL (a)	2/50 (4%)	1/49 (2%)	3/50 (6%)	9/50 (18%)
POLY-3 RATE (b)	2/43.60	1/43.08	3/47.73	9/48.59
POLY-3 PERCENT (g)	4.6%	2.3%	6.3%	18.5%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	1/36 (3%)	4/39 (10%)
FIRST INCIDENCE	705	613	709	626

**STATISTICAL TESTS**

POLY 3	P=0.003**	P=0.504N	P=0.541	P=0.039*
POLY 1.5	P=0.003**	P=0.504N	P=0.527	P=0.034*
POLY 6	P=0.004**	P=0.503N	P=0.558	P=0.047*
COCH-ARM / FISHERS	P=0.002**	P=0.508N	P=0.500	P=0.026*
MAX-ISO-POLY-3	P=0.005**	P=0.284N	P=0.367	P=0.024*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	16/50 (32%)	28/49 (57%)	45/50 (90%)	42/50 (84%)
POLY-3 RATE (b)	16/44.47	28/44.10	45/49.72	42/49.91
POLY-3 PERCENT (g)	36%	63.5%	90.5%	84.2%
TERMINAL (d)	11/32 (34%)	23/35 (66%)	33/36 (92%)	32/39 (82%)
FIRST INCIDENCE	584	600	414	610

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.006**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.007**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.006**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.010**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.003**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	43/50 (86%)	45/49 (92%)	47/50 (94%)	50/50 (100%)
POLY-3 RATE (b)	43/48.26	45/47.68	47/49.94	50/50.00
POLY-3 PERCENT (g)	89.1%	94.4%	94.1%	100%
TERMINAL (d)	27/32 (84%)	34/35 (97%)	34/36 (94%)	39/39 (100%)
FIRST INCIDENCE	522	313	414	610

**STATISTICAL TESTS**

POLY 3	P=0.016*	P=0.275	P=0.296	P=0.021*
POLY 1.5	P=0.013*	P=0.322	P=0.271	P=0.017*
POLY 6	P=0.020*	P=0.203	P=0.312	P=0.026*
COCH-ARM / FISHERS	P=0.006**	P=0.274	P=0.159	P=0.006**
MAX-ISO-POLY-3	P=0.011*	P=0.162	P=0.188	P=0.007**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	8/50 (16%)	11/49 (22%)	16/50 (32%)	22/50 (44%)
POLY-3 RATE (b)	8/44.87	11/43.89	16/48.44	22/48.95
POLY-3 PERCENT (g)	17.8%	25.1%	33%	45%
TERMINAL (d)	4/32 (13%)	7/35 (20%)	14/36 (39%)	15/39 (39%)
FIRST INCIDENCE	533	600	414	626

**STATISTICAL TESTS**

POLY 3	P=0.002**	P=0.284	P=0.073	P=0.004**
POLY 1.5	P<0.001**	P=0.289	P=0.065	P=0.003**
POLY 6	P=0.002**	P=0.284	P=0.081	P=0.005**
COCH-ARM / FISHERS	P<0.001**	P=0.288	P=0.050*	P=0.002**
MAX-ISO-POLY-3	P=0.002**	P=0.205	P=0.051	P=0.002**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Olfactory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	11/50 (22%)	19/49 (39%)	8/50 (16%)	17/50 (34%)
POLY-3 RATE (b)	11/43.64	19/43.96	8/47.93	17/48.20
POLY-3 PERCENT (g)	25.2%	43.2%	16.7%	35.3%
TERMINAL (d)	10/32 (31%)	16/35 (46%)	6/36 (17%)	14/39 (36%)
FIRST INCIDENCE	695	551	659	610

**STATISTICAL TESTS**

POLY 3	P=0.380	P=0.056	P=0.228N	P=0.206
POLY 1.5	P=0.341	P=0.056	P=0.254N	P=0.180
POLY 6	P=0.425	P=0.059	P=0.198N	P=0.239
COCH-ARM / FISHERS	P=0.268	P=0.055	P=0.306N	P=0.133
MAX-ISO-POLY-3	P=0.248	P=0.036*	P=0.169N	P=0.159

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium  
Atrophy**

**LESION RATES**

OVERALL (a)	8/50 (16%)	29/49 (59%)	49/50 (98%)	50/50 (100%)
POLY-3 RATE (b)	8/45.01	29/45.91	49/49.94	50/50.00
POLY-3 PERCENT (g)	17.8%	63.2%	98.1%	100%
TERMINAL (d)	4/32 (13%)	20/35 (57%)	36/36 (100%)	39/39 (100%)
FIRST INCIDENCE	465	564	414	610

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Olfactory Epithelium  
Necrosis**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/49 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/42.67	2/47.75	1/47.64
POLY-3 PERCENT (g)	0%	0%	4.2%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	709	656

**STATISTICAL TESTS**

POLY 3	P=0.290	(e)	P=0.259	P=0.518
POLY 1.5	P=0.277	(e)	P=0.251	P=0.512
POLY 6	P=0.304	(e)	P=0.268	P=0.525
COCH-ARM / FISHERS	P=0.253	(e)	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.210	(e)	P=0.096	P=0.181

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Olfactory Epithelium  
Respiratory Metaplasia**

**LESION RATES**

OVERALL (a)	4/50 (8%)	15/49 (31%)	48/50 (96%)	50/50 (100%)
POLY-3 RATE (b)	4/43.50	15/44.72	48/49.94	50/50.00
POLY-3 PERCENT (g)	9.2%	33.5%	96.1%	100%
TERMINAL (d)	4/32 (13%)	9/35 (26%)	35/36 (97%)	39/39 (100%)
FIRST INCIDENCE	731 (T)	564	414	610

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.004**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.004**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.005**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.004**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.002**	P<0.001**	P<0.001**

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium  
Vacuolization Cytoplasmic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	5/49 (10%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	5/43.90	1/47.61	1/47.62
POLY-3 PERCENT (g)	0%	11.4%	2.1%	2.1%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	600	726	664

**STATISTICAL TESTS**

POLY 3	P=0.431N	P=0.031*	P=0.518	P=0.518
POLY 1.5	P=0.447N	P=0.030*	P=0.512	P=0.512
POLY 6	P=0.412N	P=0.033*	P=0.525	P=0.524
COCH-ARM / FISHERS	P=0.482N	P=0.027*	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.181	P=0.010**	P=0.181	P=0.181

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	20/50 (40%)	33/49 (67%)	47/50 (94%)	29/50 (58%)
POLY-3 RATE (b)	20/43.91	33/44.88	47/49.94	29/49.03
POLY-3 PERCENT (g)	45.6%	73.5%	94.1%	59.1%
TERMINAL (d)	17/32 (53%)	26/35 (74%)	34/36 (94%)	22/39 (56%)
FIRST INCIDENCE	690	600	414	610

**STATISTICAL TESTS**

POLY 3	P=0.238	P=0.004**	P<0.001**	P=0.131
POLY 1.5	P=0.145	P=0.004**	P<0.001**	P=0.098
POLY 6	P=0.379	P=0.005**	P<0.001**	P=0.182
COCH-ARM / FISHERS	P=0.059	P=0.006**	P<0.001**	P=0.055
MAX-ISO-POLY-3	P<0.001**	P=0.002**	P<0.001**	P=0.103

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium  
Metaplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/49 (0%)	13/50 (26%)	35/50 (70%)
POLY-3 RATE (b)	0/43.50	0/42.67	13/48.03	35/49.06
POLY-3 PERCENT (g)	0%	0%	27.1%	71.4%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	9/36 (25%)	28/39 (72%)
FIRST INCIDENCE	---	---	659	610

**STATISTICAL TESTS**

POLY 3	P<0.001**	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium  
Necrosis**

**LESION RATES**

OVERALL (a)	1/50 (2%)	0/49 (0%)	6/50 (12%)	16/50 (32%)
POLY-3 RATE (b)	1/43.50	0/42.67	6/47.86	16/48.53
POLY-3 PERCENT (g)	2.3%	0%	12.5%	33%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	2/36 (6%)	11/39 (28%)
FIRST INCIDENCE	731 (T)	---	709	635

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.504N	P=0.073	P<0.001**
POLY 1.5	P<0.001**	P=0.503N	P=0.067	P<0.001**
POLY 6	P<0.001**	P=0.504N	P=0.082	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.505N	P=0.056	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.162N	P=0.038*	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Respiratory Epithelium  
Ulcer**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.50	0/42.67	0/47.59	2/47.65
POLY-3 PERCENT (g)	0%	0%	0%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	684

**STATISTICAL TESTS**

POLY 3	P=0.051	(e)	(e)	P=0.258
POLY 1.5	P=0.049*	(e)	(e)	P=0.251
POLY 6	P=0.053	(e)	(e)	P=0.266
COCH-ARM / FISHERS	P=0.047*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.050*	(e)	(e)	P=0.096

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium  
Vacuolization Cytoplasmic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/49 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	2/43.45	2/47.68	1/47.62
POLY-3 PERCENT (g)	0%	4.6%	4.2%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	551	712	664

**STATISTICAL TESTS**

POLY 3	P=0.523	P=0.237	P=0.258	P=0.518
POLY 1.5	P=0.506	P=0.236	P=0.251	P=0.512
POLY 6	P=0.541	P=0.239	P=0.268	P=0.524
COCH-ARM / FISHERS	P=0.472	P=0.242	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.256	P=0.077	P=0.096	P=0.181

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Turbinate  
Hyperostosis**

**LESION RATES**

OVERALL (a)	4/50 (8%)	23/49 (47%)	49/50 (98%)	50/50 (100%)
POLY-3 RATE (b)	4/44.15	23/44.97	49/49.98	50/50.00
POLY-3 PERCENT (g)	9.1%	51.2%	98%	100%
TERMINAL (d)	2/32 (6%)	17/35 (49%)	36/36 (100%)	39/39 (100%)
FIRST INCIDENCE	584	444	414	610

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Nose: Turbinate  
Necrosis**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/42.67	0/47.59	1/47.55
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	684

**STATISTICAL TESTS**

POLY 3	P=0.214	(e)	(e)	P=0.518
POLY 1.5	P=0.210	(e)	(e)	P=0.512
POLY 6	P=0.219	(e)	(e)	P=0.524
COCH-ARM / FISHERS	P=0.201	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.156	(e)	(e)	P=0.180

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Ovary  
Cyst**

**LESION RATES**

OVERALL (a)	8/49 (16%)	11/50 (22%)	7/50 (14%)	9/50 (18%)
POLY-3 RATE (b)	8/43.13	11/43.30	7/47.59	9/47.72
POLY-3 PERCENT (g)	18.6%	25.4%	14.7%	18.9%
TERMINAL (d)	7/32 (22%)	11/35 (31%)	7/36 (19%)	7/39 (18%)
FIRST INCIDENCE	533	731 (T)	731 (T)	664

**STATISTICAL TESTS**

POLY 3	P=0.439N	P=0.305	P=0.418N	P=0.591
POLY 1.5	P=0.468N	P=0.317	P=0.439N	P=0.569
POLY 6	P=0.407N	P=0.293	P=0.392N	P=0.595N
COCH-ARM / FISHERS	P=0.527N	P=0.323	P=0.483N	P=0.518
MAX-ISO-POLY-3	P=0.441N	P=0.222	P=0.320N	P=0.485

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Ovary  
Hemorrhage**

**LESION RATES**

OVERALL (a)	2/49 (4%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/43.63	0/43.30	0/47.59	2/47.37
POLY-3 PERCENT (g)	4.6%	0%	0%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	2/39 (5%)
FIRST INCIDENCE	47	---	---	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.525	P=0.239N	P=0.218N	P=0.664N
POLY 1.5	P=0.518	P=0.237N	P=0.224N	P=0.673N
POLY 6	P=0.532	P=0.240N	P=0.211N	P=0.655N
COCH-ARM / FISHERS	P=0.507	P=0.242N	P=0.242N	P=0.684N
MAX-ISO-POLY-3	P=0.261N	P=0.078N	P=0.075N	P=0.467N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pancreas  
Atrophy**

**LESION RATES**

OVERALL (a)	1/50 (2%)	3/50 (6%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.50	3/43.67	1/47.59	1/47.37
POLY-3 PERCENT (g)	2.3%	6.9%	2.1%	2.1%
TERMINAL (d)	1/32 (3%)	2/35 (6%)	1/36 (3%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	627	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.416N	P=0.306	P=0.740N	P=0.741N
POLY 1.5	P=0.427N	P=0.308	P=0.747N	P=0.747N
POLY 6	P=0.406N	P=0.306	P=0.732N	P=0.735N
COCH-ARM / FISHERS	P=0.450N	P=0.309	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.424N	P=0.155	P=0.475N	P=0.476N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pancreas  
Cyst**

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/43.50	2/43.52	2/47.59	1/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	4.2%	2.1%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	2/36 (6%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	673	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.519N	P=0.500	P=0.531	P=0.741N
POLY 1.5	P=0.531N	P=0.502	P=0.521	P=0.747N
POLY 6	P=0.507N	P=0.500	P=0.544	P=0.735N
COCH-ARM / FISHERS	P=0.557N	P=0.500	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.542N	P=0.280	P=0.315	P=0.476N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Parathyroid Gland  
Cyst**

**LESION RATES**

OVERALL (a)	0/23 (0%)	1/32 (3%)	2/33 (6%)	0/33 (0%)
POLY-3 RATE (b)	0/19.68	1/27.53	2/32.62	0/31.23
POLY-3 PERCENT (g)	0%	3.6%	6.1%	0%
TERMINAL (d)	0/15 (0%)	0/22 (0%)	2/27 (7%)	0/26 (0%)
FIRST INCIDENCE	---	677	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.506N	P=0.567	P=0.357	(e)
POLY 1.5	P=0.515N	P=0.569	P=0.346	(e)
POLY 6	P=0.499N	P=0.564	P=0.368	(e)
COCH-ARM / FISHERS	P=0.547N	P=0.582	P=0.343	(e)
MAX-ISO-POLY-3	P=0.391N	P=0.218	P=0.171	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Pituitary Gland: Pars Distalis  
Angiectasis**

**LESION RATES**

OVERALL (a)	1/50 (2%)	0/50 (0%)	4/50 (8%)	2/49 (4%)
POLY-3 RATE (b)	1/43.50	0/43.30	4/47.61	2/46.41
POLY-3 PERCENT (g)	2.3%	0%	8.4%	4.3%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	3/36 (8%)	1/38 (3%)
FIRST INCIDENCE	731 (T)	---	726	719

**STATISTICAL TESTS**

POLY 3	P=0.279	P=0.501N	P=0.208	P=0.523
POLY 1.5	P=0.264	P=0.500N	P=0.198	P=0.513
POLY 6	P=0.296	P=0.502N	P=0.220	P=0.532
COCH-ARM / FISHERS	P=0.236	P=0.500N	P=0.181	P=0.492
MAX-ISO-POLY-3	P=0.170	P=0.160N	P=0.111	P=0.306

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis  
Cyst**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	2/49 (4%)
POLY-3 RATE (b)	0/43.50	0/43.30	3/47.59	2/46.37
POLY-3 PERCENT (g)	0%	0%	6.3%	4.3%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	2/38 (5%)
FIRST INCIDENCE	---	---	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.117	(e)	P=0.136	P=0.252
POLY 1.5	P=0.109	(e)	P=0.130	P=0.246
POLY 6	P=0.125	(e)	P=0.143	P=0.258
COCH-ARM / FISHERS	P=0.096	(e)	P=0.121	P=0.242
MAX-ISO-POLY-3	P=0.107	(e)	P=0.052	P=0.091

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis  
Hyperplasia**

**LESION RATES**

OVERALL (a)	8/50 (16%)	15/50 (30%)	16/50 (32%)	10/49 (20%)
POLY-3 RATE (b)	8/43.50	15/43.60	16/47.66	10/46.76
POLY-3 PERCENT (g)	18.4%	34.4%	33.6%	21.4%
TERMINAL (d)	8/32 (25%)	14/35 (40%)	14/36 (39%)	8/38 (21%)
FIRST INCIDENCE	731 (T)	649	718	635

**STATISTICAL TESTS**

POLY 3	P=0.484N	P=0.070	P=0.078	P=0.463
POLY 1.5	P=0.531N	P=0.074	P=0.067	P=0.436
POLY 6	P=0.431N	P=0.067	P=0.093	P=0.495
COCH-ARM / FISHERS	P=0.464	P=0.077	P=0.050*	P=0.379
MAX-ISO-POLY-3	P=0.192	P=0.042*	P=0.055	P=0.366



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin  
Inflammation**

**LESION RATES**

OVERALL (a)	1/50 (2%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.80	0/43.30	3/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	0%	6.3%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	0/39 (0%)
FIRST INCIDENCE	649	---	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.456N	P=0.502N	P=0.336	P=0.484N
POLY 1.5	P=0.468N	P=0.500N	P=0.326	P=0.489N
POLY 6	P=0.443N	P=0.504N	P=0.347	P=0.480N
COCH-ARM / FISHERS	P=0.493N	P=0.500N	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.282N	P=0.161N	P=0.185	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin  
Ulcer**

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.94	2/43.73	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	604	673	---	---

**STATISTICAL TESTS**

POLY 3	P=0.182N	P=0.498	P=0.484N	P=0.485N
POLY 1.5	P=0.185N	P=0.501	P=0.489N	P=0.489N
POLY 6	P=0.179N	P=0.497	P=0.478N	P=0.481N
COCH-ARM / FISHERS	P=0.193N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.171N	P=0.279	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Spleen  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	2/50 (4%)	4/50 (8%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	2/43.64	4/44.18	4/47.64	2/47.71
POLY-3 PERCENT (g)	4.6%	9.1%	8.4%	4.2%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	695	627	718	635

**STATISTICAL TESTS**

POLY 3	P=0.443N	P=0.343	P=0.379	P=0.661N
POLY 1.5	P=0.461N	P=0.342	P=0.365	P=0.671N
POLY 6	P=0.424N	P=0.346	P=0.395	P=0.650N
COCH-ARM / FISHERS	P=0.501N	P=0.339	P=0.339	P=0.691N
MAX-ISO-POLY-3	P=0.449N	P=0.206	P=0.243	P=0.465N

---

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Spleen  
 Hyperplasia Lymphoid**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/43.50	0/43.30	1/47.86	0/47.37
POLY-3 PERCENT (g)	4.6%	0%	2.1%	0%
TERMINAL (d)	2/32 (6%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	---	659	---

**STATISTICAL TESTS**

POLY 3	P=0.175N	P=0.238N	P=0.467N	P=0.219N
POLY 1.5	P=0.179N	P=0.237N	P=0.478N	P=0.224N
POLY 6	P=0.171N	P=0.239N	P=0.452N	P=0.213N
COCH-ARM / FISHERS	P=0.186N	P=0.247N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.077N	P=0.077N	P=0.263N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/43.30	4/47.62	1/47.37
POLY-3 PERCENT (g)	0%	0%	8.4%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	---	---	722	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.299	(e)	P=0.073	P=0.517
POLY 1.5	P=0.282	(e)	P=0.069	P=0.512
POLY 6	P=0.318	(e)	P=0.078	P=0.523
COCH-ARM / FISHERS	P=0.253	(e)	P=0.059	P=0.500
MAX-ISO-POLY-3	P=0.107	(e)	P=0.029*	P=0.179

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach  
Inflammation**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.10	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	584	---	---	---

**STATISTICAL TESTS**

POLY 3	P=0.112N	P=0.241N	P=0.221N	P=0.222N
POLY 1.5	P=0.113N	P=0.238N	P=0.226N	P=0.226N
POLY 6	P=0.111N	P=0.244N	P=0.215N	P=0.217N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.080N	P=0.076N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Stomach, Glandular  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Thymus  
Cyst**

**LESION RATES**

OVERALL (a)	1/47 (2%)	0/47 (0%)	0/45 (0%)	0/47 (0%)
POLY-3 RATE (b)	1/41.66	0/41.15	0/42.73	0/44.64
POLY-3 PERCENT (g)	2.4%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/34 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	604	---	---	---

**STATISTICAL TESTS**

POLY 3	P=0.311N	P=0.502N	P=0.495N	P=0.486N
POLY 1.5	P=0.311N	P=0.500N	P=0.499N	P=0.490N
POLY 6	P=0.311N	P=0.504N	P=0.490N	P=0.482N
COCH-ARM / FISHERS	P=0.308N	P=0.500N	P=0.511N	P=0.500N
MAX-ISO-POLY-3	P=0.125N	P=0.162N	P=0.161N	P=0.158N

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Thyroid Gland  
Cyst**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	7/50 (14%)	3/50 (6%)
POLY-3 RATE (b)	0/43.50	2/43.60	7/47.61	3/48.13
POLY-3 PERCENT (g)	0%	4.6%	14.7%	6.2%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	6/36 (17%)	1/39 (3%)
FIRST INCIDENCE	---	649	726	610

**STATISTICAL TESTS**

POLY 3	P=0.164	P=0.238	P=0.011*	P=0.138
POLY 1.5	P=0.145	P=0.238	P=0.010**	P=0.132
POLY 6	P=0.187	P=0.237	P=0.012*	P=0.146
COCH-ARM / FISHERS	P=0.117	P=0.247	P=0.006**	P=0.121
MAX-ISO-POLY-3	P=0.039*	P=0.076	P=0.005**	P=0.054

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Thyroid Gland: Follicular Cell  
Hyperplasia**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/44.71	0/43.30	1/47.59	0/47.37
POLY-3 PERCENT (g)	4.5%	0%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	465	---	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.175N	P=0.244N	P=0.478N	P=0.225N
POLY 1.5	P=0.179N	P=0.240N	P=0.485N	P=0.228N
POLY 6	P=0.171N	P=0.248N	P=0.470N	P=0.221N
COCH-ARM / FISHERS	P=0.186N	P=0.247N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.077N	P=0.083N	P=0.269N	P=0.076N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Tooth: Dentine Malformation**

**LESION RATES**

OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/1 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Uterus  
Angiectasis**

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	1/43.50	1/43.30	1/47.59	4/47.37
POLY-3 PERCENT (g)	2.3%	2.3%	2.1%	8.5%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	1/36 (3%)	4/39 (10%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.079	P=0.760	P=0.740N	P=0.206
POLY 1.5	P=0.075	P=0.760N	P=0.747N	P=0.197
POLY 6	P=0.083	P=0.759	P=0.732N	P=0.215
COCH-ARM / FISHERS	P=0.067	P=0.753N	P=0.753N	P=0.181
MAX-ISO-POLY-3	P=0.110	P=0.498	P=0.475N	P=0.109

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Uterus  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.99	0/43.30	2/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	0%	4.2%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	2/36 (6%)	0/39 (0%)
FIRST INCIDENCE	584	---	731 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.429N	P=0.503N	P=0.527	P=0.485N
POLY 1.5	P=0.438N	P=0.501N	P=0.519	P=0.489N
POLY 6	P=0.419N	P=0.506N	P=0.538	P=0.481N
COCH-ARM / FISHERS	P=0.456N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.332N	P=0.162N	P=0.311	P=0.158N

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Uterus  
Thrombosis**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	2/43.58	0/43.30	0/47.59	3/47.37
POLY-3 PERCENT (g)	4.6%	0%	0%	6.3%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	0/36 (0%)	3/39 (8%)
FIRST INCIDENCE	712	---	---	731 (T)

**STATISTICAL TESTS**

POLY 3	P=0.261	P=0.238N	P=0.218N	P=0.538
POLY 1.5	P=0.255	P=0.237N	P=0.224N	P=0.526
POLY 6	P=0.267	P=0.240N	P=0.211N	P=0.550
COCH-ARM / FISHERS	P=0.247	P=0.247N	P=0.247N	P=0.500
MAX-ISO-POLY-3	P=0.137	P=0.077N	P=0.076N	P=0.363

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Uterus: Endometrium  
 Hyperplasia Cystic

**LESION RATES**

OVERALL (a)	26/50 (52%)	18/50 (36%)	21/50 (42%)	27/50 (54%)
POLY-3 RATE (b)	26/44.65	18/46.09	21/48.64	27/49.18
POLY-3 PERCENT (g)	58.2%	39.1%	43.2%	54.9%
TERMINAL (d)	21/32 (66%)	10/35 (29%)	15/36 (42%)	19/39 (49%)
FIRST INCIDENCE	592	533	659	610

**STATISTICAL TESTS**

POLY 3	P=0.439	P=0.048N*	P=0.103N	P=0.453N
POLY 1.5	P=0.385	P=0.057N	P=0.135N	P=0.522N
POLY 6	P=0.498	P=0.038N*	P=0.072N	P=0.372N
COCH-ARM / FISHERS	P=0.285	P=0.079N	P=0.212N	P=0.500
MAX-ISO-POLY-3	P=0.199N	P=0.032N*	P=0.078N	P=0.376N

**LEGEND**

- (a) Number of tumor-bearing animals/number of animals examined at site.
  - (b) Number of tumor-bearing animals/Poly-3 number
  - (d) Observed incidence at terminal kill.
  - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
  - (e) Value of Statistic cannot be computed.
  - (g) Poly-3 adjusted lifetime tumor incidence.
  - (I) Interim sacrifice
  - (T) Terminal sacrifice
  - # Tumor rates based on numbers of animals necropsied.
  - \* To the right of any statistical result, indicates significance at ( $P \leq 0.05$ ).
  - \*\* To the right of any statistical result, indicates significance at ( $P \leq 0.01$ ).
  - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.  
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

\*\*\* END OF REPORT \*\*\*